Fulcrum Therapeutics (FULC) director awarded 32,000 stock options
Rhea-AI Filing Summary
Fulcrum Therapeutics director Katina Dorton received a new stock option award covering 32,000 shares of Common Stock. The option carries an exercise price of $3.66 per share and expires on June 29, 2036. It was granted at no upfront cost and is scheduled to vest in full on the first anniversary of the June 30, 2026 grant date or earlier, immediately before the first annual stockholder meeting after the grant date, subject to continued service. Following this grant, Dorton holds 32,000 stock options directly from this award.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Dorton Katina
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 32,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 32,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 32,000 options
Exercise price: $3.66 per share
Expiration date: June 29, 2036
+2 more
5 metrics
Stock options granted
32,000 options
Grant on June 30, 2026 to director Katina Dorton
Exercise price
$3.66 per share
Exercise price for 32,000 option shares
Expiration date
June 29, 2036
Option expiration for 32,000-share grant
Shares underlying options
32,000 shares
Underlying Fulcrum Therapeutics Common Stock
Total derivative holdings after grant
32,000 options
Total stock options reported following this transaction
Key Terms
Stock Option (right to buy), Grant, award, or other acquisition, vesting, Common Stock
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
vesting financial
"is scheduled to vest with respect to all shares on the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Fulcrum Therapeutics (FULC) director Katina Dorton receive in this Form 4?
Katina Dorton received a stock option grant for 32,000 shares of Fulcrum Therapeutics Common Stock. The option was awarded at no upfront cost and represents a compensation-related acquisition rather than an open-market share purchase or sale.
What is the exercise price of Katina Dorton’s new Fulcrum Therapeutics stock options?
The stock options have an exercise price of $3.66 per share. This means Dorton can buy up to 32,000 Fulcrum Therapeutics Common Stock shares at $3.66 each once the options are vested and exercisable, subject to the stated terms.
When do Katina Dorton’s Fulcrum Therapeutics stock options vest?
The options are scheduled to vest with respect to all 32,000 shares on the first anniversary of the June 30, 2026 grant date. They may alternatively vest earlier, immediately before the first annual meeting of stockholders after the grant date, subject to continued service.
When do the Fulcrum Therapeutics stock options granted to Katina Dorton expire?
The stock options granted to Katina Dorton expire on June 29, 2036. After this expiration date, any unexercised portion of the 32,000-share option will no longer be exercisable, so the exercise opportunity is limited to the period before that date.
How many Fulcrum Therapeutics derivative securities does Katina Dorton hold after this transaction?
Following this transaction, Katina Dorton holds 32,000 stock options as reported. These options relate to 32,000 shares of Fulcrum Therapeutics Common Stock and are held directly, reflecting the full amount of the newly granted award.